Skip to main content
. 2023 Aug 9;9(8):e18920. doi: 10.1016/j.heliyon.2023.e18920

Table 9.

Effect of cenobamate, YKP3090, and YKP1983 on the rotarod test and minimal motor impairment in rats (multiple studies).

Study Type (STUDY) Test Compound Route & Dose N per dose tested Time of Test (post-dose in h) TD50 mg/kg (95% CI)
Rotarod test (Q) Cenobamate PO 150, 200, 250 mg/kg 8 4 195.7 (158.0–242.5)
Rotarod test (R) Cenobamate PO 100, 150, 200, 250 mg/kg 6 1
2
347.5 (146.7–823.2)
244.4 (88.2–677.2)
Rotarod test (S) Cenobamate PO 10, 30, 100, 250 mg/kg (3 batches 1401-1401-07-001; 1401-1401-05-501; DIT040503) 6 0.5 to 5 101.6 (27.9–220.1)
6 104.1 (40.0–204.4)
6 100.4 (−2.0-305.9)
Minimal motor impairment (NINDS) Cenobamate PO 25, 50, 75, 100 mg/kg 8 1 50.7 (35.7–63.0)
YKP3090 PO 50, 100, 150 mg/kg 8 1 <150a (N/A)
YKP1983 PO 50, 75, 120 mg/kg 8 1 81.1 (61.1–112)
Cenobamate IP 15, 30, 40, 50, 60 mg/kg 8 0.25 38.9 (32.2–43.9)
YKP3090 IP 10, 20, 25, 50,75, 100 mg/kg 8 0.5 50.9 (33.1–67.8)
YKP1983 IP 2, 7.5, 8, 15, 30, 50, 60, 73 mg/kg 4–12 0.5 53.3 (41.5–62.2)

aTD50 could not be calculated but estimated to be 150 mg/kg PO or less; h, hours; IP, intraperitoneal; NINDS, National Institute of Neurological Disorders and Stroke; PO, oral; RT, rotarod test; TD50, median neurotoxic dose.